Tag: Neurodegenerative disease

An estimated 7.2 million Americans age 65 and older are living with Alzheimer's in 2025 [1.7.2]. This staggering number fuels the urgent search for effective treatments, leading many to ask: What is the miracle drug for Alzheimer's?

While animal studies have shown that ibuprofen can reduce neuroinflammation and aid recovery in specific conditions, it is not recommended for brain inflammation following acute head injuries due to the increased risk of bleeding.

Riluzole is the active ingredient in several FDA-approved medications for treating amyotrophic lateral sclerosis (ALS), which can sometimes lead to confusion about its different names. To address the question of **what is another name for riluzole?**, it is important to understand that the drug is sold under a few distinct brand names and forms, including tablets, a liquid suspension, and an oral film. These different formulations were developed to meet the varying needs of patients, especially those who experience swallowing difficulties as the disease progresses.

In July 2024, the U.S. Food and Drug Administration (FDA) approved donanemab, also known as Kisunla, for the treatment of early symptomatic Alzheimer's disease. If you are wondering **what is the Eli Lilly memory drug**, Kisunla represents a significant advancement by targeting the underlying pathology of the disease rather than just managing symptoms.

Parkinson's disease is the world's fastest-growing neurological disorder, with projections suggesting over 25 million people could be affected by 2050 [1.6.1, 1.6.3]. This escalating health challenge drives a pressing search for better treatments. So, what is the new pill for Parkinson's disease? Several promising options have recently emerged.

In the United States, approximately 2% of ALS cases are the genetic form known as SOD1-ALS [1.8.3]. For these patients, a targeted therapy approved in 2023 represents a major advancement. So, what is the newest drug for ALS, and how does it fit into the evolving landscape of treatment?

Motor neuron disease (MND) is a progressive neurological disorder that damages motor neurons over time. The medication most commonly identified as an MND tablet is Riluzole, which is approved to help slow the disease's progression, particularly in patients with amyotrophic lateral sclerosis (ALS), the most common form of MND.

With nearly 90,000 people diagnosed with Parkinson's disease in the U.S. each year, understanding treatment is crucial [1.3.3]. The core question for many is, **what replaces dopamine in Parkinson's disease?** This article explores the primary medications designed to replenish or mimic dopamine, managing the disease's motor symptoms.

As of 2025, the U.S. Food and Drug Administration (FDA) has granted full approval to two amyloid antibodies for treating early-stage Alzheimer's disease: lecanemab (Leqembi) and donanemab (Kisunla) [1.2.1, 1.2.3, 1.2.4]. This article answers: **what amyloid antibodies are FDA approved** and details their use.

While fenofibrate is primarily known as a lipid-lowering medication for hypercholesterolemia and hypertriglyceridemia, preclinical research suggests that it also exerts several pharmacological effects on the central nervous system (CNS). These intriguing effects stem from its primary mechanism of action: activating the nuclear receptor peroxisome proliferator-activated receptor alpha ($$PPAR-\alpha$$).